We use cookies, including third-party cookies from Google to serve personalized ads through AdSense, to operate this site and understand how it is used. By continuing to browse, you accept this use. See our Privacy Policy and Terms of Use for details, including how to opt out of personalized advertising.
Accept
Health Works CollectiveHealth Works CollectiveHealth Works Collective
  • Health
    • Mental Health
  • Policy and Law
    • Global Healthcare
    • Medical Ethics
  • Medical Innovations
  • News
  • Wellness
  • Tech
Search
© 2023 HealthWorks Collective. All Rights Reserved.
Reading: Lipitor: How Pfizer Hopes to Slow the Decline
Share
Notification Show More
Font ResizerAa
Health Works CollectiveHealth Works Collective
Font ResizerAa
Search
Follow US
  • About
  • Contact
  • Privacy
© 2023 HealthWorks Collective. All Rights Reserved.
Health Works Collective > Business > Lipitor: How Pfizer Hopes to Slow the Decline
Business

Lipitor: How Pfizer Hopes to Slow the Decline

DavidEWilliams
DavidEWilliams
Share
4 Min Read
SHARE

By all rights, Pfizer’s Lipitor revenues should drop like a stone once the drug loses US patent protection at the end of the month. And I think it’s likely that over time prescription Lipitor sales will whither away. Pfizer’s original plan was to replace Lipitor sales with those of torcetrapib, a new and improved drug that would sustain and expand the Pfizer franchise. That didn’t work out when the drug failed in late stage development.

By all rights, Pfizer’s Lipitor revenues should drop like a stone once the drug loses US patent protection at the end of the month. And I think it’s likely that over time prescription Lipitor sales will whither away. Pfizer’s original plan was to replace Lipitor sales with those of torcetrapib, a new and improved drug that would sustain and expand the Pfizer franchise. That didn’t work out when the drug failed in late stage development.

Now Pfizer is left with the tough task of defending Lipitor against cheaper, but theoretically identical, products. According to the Wall Street Journal (Forget Generics, Pfizer Has Plenty of ‘Lipitor for You’) the company is confident that it can succeed, at least to a reasonable degree.

Pfizer said Tuesday it is striking deals with drug-benefit plans and providing discounts to patients to encourage continued use of branded Lipitor, and to preserve a big chunk of its nearly $11 billion in annual sales.

More Read

chat bubble
9 Success Keys: How to Make Your Social Media Truly Engaging
How Much Does a Knee Replacement Cost? A Question From a NJ Transit Bus
HIMSS Analytics 3rd Annual Mobile Survey
Socioeconomic Factors Crucial for Provider Performance Measurement in a Value-Based Paradigm
Don’t Forget Importance of Trust, Listening in Healthcare Delivery

If Pfizer succeeds, it will only be because of the strange and somewhat dysfunctional structure of the health insurance market.

In general, health insurers seek to pay less rather than more for a drug. They do this with formularies, which discourage the use of pricey drugs through higher co-pays and prior authorization requirements. When a generic is available, there should always be a significant financial incentive for the patient to choose it rather than the branded product. However, Pfizer is likely to undermine this in a couple of ways:

  • By providing coupons or co-pay cards to patients, which cancel out the differential between the co-pay for Lipitor and the generic equivalent and effectively block health plans’ attempts to give patients “skin in the game”
  • Making rebate or market share incentive deals with pharmacy benefit managers (PBMs) to enable those companies to make significantly more margin from Lipitor than from the generic

These deals cut into Pfizer’s margins but preserve sales revenue, cost the patient nothing, and put money in the pockets of PBMs.

So who loses?

The main losers are whoever is paying health insurance premiums, i.e., employers and individuals. Everyone’s premium is higher than it could be to the extent that Pfizer is successful in its strategy. That’s because ultimately health plans end up paying more when Lipitor is used rather than a generic.

It’s worth noting that Massachusetts is the only state in the country that forbids the use of co-pay coupons by drug makers. I support that policy because it helps contain costs.

 

 

 


TAGGED:LipitorPfizerpharmaceuticals
Share This Article
Facebook Copy Link Print
Share

Stay Connected

1.5KFollowersLike
4.5KFollowersFollow
2.8KFollowersPin
136KSubscribersSubscribe

Latest News

The Nervous System Reset Guide: Simple Ways To Manage Stress -- AI-generated illustration
The Nervous System Reset Guide: Simple Ways To Manage Stress
Infographics Mental Health
November 14, 2026
Flat editorial illustration: A single digital quality-management platform connects document control, electronic approval, audit r
6 Best QMS Software Platforms for ISO 13485 and FDA Part 820 (QMSR)
Global Healthcare Policy & Law
November 12, 2026
Flat editorial illustration: Healthcare editorial illustration about accurate patient intake connecting registration, clinical re
The Role of Patient Data Accuracy in Healthcare Operations
Global Healthcare Policy & Law
November 11, 2026
Flat editorial illustration: Healthcare ethics-and-law training, shown through a coached clinical role-play where structured disc
Medical Ethics and the Law: The Training Behind Professionals Who Resolve Healthcare Disputes
Uncategorized
November 6, 2026

You Might also Like

Dare to Be Adequate: Hospital Advertising That Fails (and What to Do Instead)

February 20, 2013
diabetes costs
FinancePolicy & LawPublic Health

Dissecting Diabetes: Costs and Chronic Disease Impact

April 12, 2014

Managing the Mobile Workforce

February 2, 2012

Transforming Medicaid via the Medical Home Model

February 24, 2013
Subscribe
Subscribe to our newsletter to get our newest articles instantly!
Follow US
© 2008-2026 HealthWorks Collective. All Rights Reserved.
  • About
  • Contact
  • Privacy
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?